Nancy M. Allen LaPointe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nancy M. Allen LaPointe has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Andrzej Stanislaw Kosinski
Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA
2 shared publications Andrzej S. Kosinski
Department of Biostatistics and Bioinformatics Duke University School of Medicine Durham North Carolina USA
1 shared publicationB. Judson Colley
Jackson Heart Clinic, Jackson, Mississippi (B.J.C.)
1 shared publication- Daniel D. Matlock
Adult and Child Center for Outcomes Research and Delivery Science, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States
1 shared publication Daniel Haithcock
Georgia Arrhythmia Associates, Macon, Georgia (D.H.)
1 shared publicationDavid S. Hirsh
Department of Medicine, Emory University, Atlanta, Georgia (D.S.H.)
1 shared publication
Latest Publications
- 1 May 2023
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 176 (5) , 615-623
Facilitating Shared Decision Making Among Black Patients at Risk for Sudden Cardiac Arrest
Racial disparities in implantable cardioverter-defibrillator (ICD) implantation are multifactorial and are partly explained by higher refusal rates. To assess the effectiveness of a video decision support tool for Black patients eligible for an ICD. Multicenter, randomized clinical trial conducted between September 2016 and April 2020. (ClinicalTrials.gov: NCT02819973). Fourteen academic and community-based electrophysiology clinics in the United States. Black adults with heart failure who were eligible for a primary prevention ICD. An encounter-based video decision support tool or usual care. The primary outcome was the decision regarding ICD implantation. Additional outcomes included patient knowledge, decisional conflict, ICD implantation within 90 days, the effect of racial concordance on outcomes, and the time patients spent with clinicians. Of the 330 randomly assigned patients, 311 contributed data for the primary outcome. Among those randomly assigned to the video group, assent to ICD implantation was 58.6% compared with 59.4% in the usual care group (difference, -0.8 percentage point [95% CI, -13.2 to 11.1 percentage points]). Compared with usual care, participants in the video group had a higher mean knowledge score (difference, 0.7 [CI, 0.2 to 1.1]) and a similar decisional conflict score (difference, -2.6 [CI, -5.7 to 0.4]). The ICD implantation rate within 90 days was 65.7%, with no differences by intervention. Participants randomly assigned to the video group spent less time with their clinician than those in the usual care group (mean, 22.1 vs. 27.0 minutes; difference, -4.9 minutes [CI, -9.4 to -0.3 minutes]). Racial concordance between video and study participants did not affect study outcomes. The Centers for Medicare & Medicaid Services implemented a requirement for shared decision making for ICD implantation during the study. A video-based decision support tool increased patient knowledge but did not increase assent to ICD implantation. Patient-Centered Outcomes Research Institute.
- 1 May 2023
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 176 (5) , 615-623
Facilitating Shared Decision Making Among Black Patients at Risk for Sudden Cardiac Arrest
Racial disparities in implantable cardioverter-defibrillator (ICD) implantation are multifactorial and are partly explained by higher refusal rates. To assess the effectiveness of a video decision support tool for Black patients eligible for an ICD. Multicenter, randomized clinical trial conducted between September 2016 and April 2020. (ClinicalTrials.gov: NCT02819973). Fourteen academic and community-based electrophysiology clinics in the United States. Black adults with heart failure who were eligible for a primary prevention ICD. An encounter-based video decision support tool or usual care. The primary outcome was the decision regarding ICD implantation. Additional outcomes included patient knowledge, decisional conflict, ICD implantation within 90 days, the effect of racial concordance on outcomes, and the time patients spent with clinicians. Of the 330 randomly assigned patients, 311 contributed data for the primary outcome. Among those randomly assigned to the video group, assent to ICD implantation was 58.6% compared with 59.4% in the usual care group (difference, -0.8 percentage point [95% CI, -13.2 to 11.1 percentage points]). Compared with usual care, participants in the video group had a higher mean knowledge score (difference, 0.7 [CI, 0.2 to 1.1]) and a similar decisional conflict score (difference, -2.6 [CI, -5.7 to 0.4]). The ICD implantation rate within 90 days was 65.7%, with no differences by intervention. Participants randomly assigned to the video group spent less time with their clinician than those in the usual care group (mean, 22.1 vs. 27.0 minutes; difference, -4.9 minutes [CI, -9.4 to -0.3 minutes]). Racial concordance between video and study participants did not affect study outcomes. The Centers for Medicare & Medicaid Services implemented a requirement for shared decision making for ICD implantation during the study. A video-based decision support tool increased patient knowledge but did not increase assent to ICD implantation. Patient-Centered Outcomes Research Institute.
- 21 June 2022
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 45 (8) , 930-939
Cardiac resynchronization therapy outcomes with left ventricular lead concordant with latest mechanical activation: A meta‐analysis
Background For cardiac resynchronization therapy (CRT), image-guided approaches targeting left ventricular (LV) lead placement at the site of latest mechanical activation had inconsistent outcomes. We examined evidence for improved CRT outcomes when LV lead placement concordant with latest mechanical activation occurred. Methods A review of EMBASE and PubMed was performed for randomized controlled trials or prospective observational studies from October 2008 through October 2020 comparing outcomes with concordant versus discordant LV lead placement. Meta-analyses were performed to assess the association between concordance and death, death or heart failure (HF) hospitalization, >= 15% reduction in LV end systolic volume (LVESV), and changes in LVESV or ejection fraction (LVEF). Results From 5897 citations, nine publications (eight studies) with 1355 patients were selected; 975 with a concordant LV lead and 380 with a discordant lead. Mean age was 66-68 years, 82% were male, and 64% had ischemic cardiomyopathy. Meta-analyses demonstrated a statistically significant reduction in death/HF hospitalization at 2 years (OR 0.38; 95% CI 0.16, 0.92) and LVESV at 6 months (mean difference [MD] -13.4%; 95% CI -6.7%, -20.0%), and an increase in LVEF (MD 4.03; 95% CI 0.77, 7.30) with the concordant LV lead. There were trends toward decreased death at 2 years (OR 0.49; 95% CI 0.19, 1.23) and >= 15% reduction in LVESV at 6 months (OR 3.81; 95% CI 0.24, 61.24) with concordant LV lead placement. Conclusion A concordant LV lead was associated with better CRT outcomes. Further study of feasible methods to achieve LV lead concordance is needed.
- 21 June 2022
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 45 (8) , 930-939
Cardiac resynchronization therapy outcomes with left ventricular lead concordant with latest mechanical activation: A meta‐analysis
Background For cardiac resynchronization therapy (CRT), image-guided approaches targeting left ventricular (LV) lead placement at the site of latest mechanical activation had inconsistent outcomes. We examined evidence for improved CRT outcomes when LV lead placement concordant with latest mechanical activation occurred. Methods A review of EMBASE and PubMed was performed for randomized controlled trials or prospective observational studies from October 2008 through October 2020 comparing outcomes with concordant versus discordant LV lead placement. Meta-analyses were performed to assess the association between concordance and death, death or heart failure (HF) hospitalization, >= 15% reduction in LV end systolic volume (LVESV), and changes in LVESV or ejection fraction (LVEF). Results From 5897 citations, nine publications (eight studies) with 1355 patients were selected; 975 with a concordant LV lead and 380 with a discordant lead. Mean age was 66-68 years, 82% were male, and 64% had ischemic cardiomyopathy. Meta-analyses demonstrated a statistically significant reduction in death/HF hospitalization at 2 years (OR 0.38; 95% CI 0.16, 0.92) and LVESV at 6 months (mean difference [MD] -13.4%; 95% CI -6.7%, -20.0%), and an increase in LVEF (MD 4.03; 95% CI 0.77, 7.30) with the concordant LV lead. There were trends toward decreased death at 2 years (OR 0.49; 95% CI 0.19, 1.23) and >= 15% reduction in LVESV at 6 months (OR 3.81; 95% CI 0.24, 61.24) with concordant LV lead placement. Conclusion A concordant LV lead was associated with better CRT outcomes. Further study of feasible methods to achieve LV lead concordance is needed.
- Open Access
- 20 May 2022
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 2022, 1-10
Outcomes of Cardiac Resynchronization Therapy with Image-Guided Left Ventricular Lead Placement at the Site of Latest Mechanical Activation: A Systematic Review and Meta-Analysis
Aim. To assess evidence for an image-guided approach for cardiac resynchronization therapy (CRT) that targets left ventricular (LV) lead placement at the segment of latest mechanical activation. Methods. A systematic review of EMBASE and PubMed was performed for randomized controlled trials (RCTs) and prospective observational studies from October 2008 through October 2020 that compared an image-guided CRT approach with a non-image-guided approach for LV lead placement. Meta-analyses were performed to assess the association between the image-guided approach and NYHA class improvement or changes in end-systolic volume (LVESV), end-diastolic volume (LVEDV), and ejection fraction (LVEF). Results. From 5897 citations, 5 RCTs including 818 patients (426 image-guided and 392 non-image-guided) were identified. The mean age ranged from 66 to 71 years, 76 were male, and 53 had ischemic cardiomyopathy. Speckle tracking echocardiography was the primary image-guided method in all studies. LV lead placement within the segment of the latest mechanical activation (concordant) was achieved in the image-guided arm in 45 of the evaluable patients. There was a statistically significant improvement in the NYHA class at 6 months (odds ratio 1.66; 95 confidence interval (CI) [1.02, 2.69]) with the image-guided approach, but no statistically significant change in LVESV (MD 7.1; 95 CI [16.0, 1.8]), LVEDV (MD 5.2; 95 CI [15.8, 5.4]), or LVEF (MD 0.68; 95 CI [4.36, 5.73]) versus the non-image-guided approach. Conclusion. The image-guided CRT approach was associated with improvement in the NYHA class but not echocardiographic measures, possibly due to the small sample size and a low rate of concordant LV lead placement despite using the image-guided approach. Therefore, our meta-analysis was not able to identify consistent improvement in CRT outcomes with an image-guided approach.
- 20 May 2022
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 2022, 1-10
Open AccessOutcomes of Cardiac Resynchronization Therapy with Image-Guided Left Ventricular Lead Placement at the Site of Latest Mechanical Activation: A Systematic Review and Meta-Analysis
Aim. To assess evidence for an image-guided approach for cardiac resynchronization therapy (CRT) that targets left ventricular (LV) lead placement at the segment of latest mechanical activation. Methods. A systematic review of EMBASE and PubMed was performed for randomized controlled trials (RCTs) and prospective observational studies from October 2008 through October 2020 that compared an image-guided CRT approach with a non-image-guided approach for LV lead placement. Meta-analyses were performed to assess the association between the image-guided approach and NYHA class improvement or changes in end-systolic volume (LVESV), end-diastolic volume (LVEDV), and ejection fraction (LVEF). Results. From 5897 citations, 5 RCTs including 818 patients (426 image-guided and 392 non-image-guided) were identified. The mean age ranged from 66 to 71 years, 76 were male, and 53 had ischemic cardiomyopathy. Speckle tracking echocardiography was the primary image-guided method in all studies. LV lead placement within the segment of the latest mechanical activation (concordant) was achieved in the image-guided arm in 45 of the evaluable patients. There was a statistically significant improvement in the NYHA class at 6 months (odds ratio 1.66; 95 confidence interval (CI) [1.02, 2.69]) with the image-guided approach, but no statistically significant change in LVESV (MD 7.1; 95 CI [16.0, 1.8]), LVEDV (MD 5.2; 95 CI [15.8, 5.4]), or LVEF (MD 0.68; 95 CI [4.36, 5.73]) versus the non-image-guided approach. Conclusion. The image-guided CRT approach was associated with improvement in the NYHA class but not echocardiographic measures, possibly due to the small sample size and a low rate of concordant LV lead placement despite using the image-guided approach. Therefore, our meta-analysis was not able to identify consistent improvement in CRT outcomes with an image-guided approach.
- Open Access
- 3 September 2013
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 13 (6) , 481-483
The potential impact of pharmacogenetic testing on medication adherence
Poor medication adherence is a well-known problem, particularly in patients with chronic conditions, and is associated with significant morbidity, mortality and health-care costs. Multi-faceted and personalized interventions have shown the greatest success. Pharmacogenetic (PGx) testing may serve as another tool to boost patients’ confidence in the safety and efficacy of prescribed medications. Here, we consider the potential impact (positively or negatively) of PGx testing on medication-taking behavior.
- 3 September 2013
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 13 (6) , 481-483
Open AccessThe potential impact of pharmacogenetic testing on medication adherence
Poor medication adherence is a well-known problem, particularly in patients with chronic conditions, and is associated with significant morbidity, mortality and health-care costs. Multi-faceted and personalized interventions have shown the greatest success. Pharmacogenetic (PGx) testing may serve as another tool to boost patients’ confidence in the safety and efficacy of prescribed medications. Here, we consider the potential impact (positively or negatively) of PGx testing on medication-taking behavior.